A Milestone in Global Health: A New Polio Vaccine Approved for Emergency Use

Explore & learn more

A Milestone in Global Health: A New Polio Vaccine Approved for Emergency Use

Nurse administrating the polio vaccine

In a significant stride towards eradicating a debilitating disease, a new polio vaccine has achieved WHO prequalification. This development represents a crucial milestone in global health, where effective vaccination remains our strongest defence. With a novel design intended to tackle a persistent challenge of the virus, this vaccine is poised to bolster our fight against the spread of poliomyelitis. Years of research, collaboration, and testing have culminated in this achievement, promising new hope for a world free of polio.

Why a New Vaccine?

Despite widespread immunization campaigns, polio has proven a tenacious adversary. The disease, which primarily affects young children, can lead to irreversible paralysis and even death. While substantial progress has been made in the fight against this disease, certain strains of the virus, particularly circulating vaccine-derived poliovirus (cVDPV), a strain that emerges when the weakened virus in oral vaccines mutates back into a more virulent form, continue to circulate in regions with suboptimal vaccine coverage.

The challenges posed by cVDPV are compounded by logistical and resource limitations in many affected regions, requiring more effective and adaptable vaccination solutions. As the world approaches the final stages of this virus’ eradication, there’s a pressing need for a safe vaccine that can curb the spread of these resistant strains.

To counter the threat of strains such as cVDPV, the new novel oral polio vaccine type 2 (nOPV2) was developed. It is designed to be genetically stable, therefore reducing the risk of reversion to a more virulent form and thereby improving overall safety and effectiveness. After rigorous testing and safety assessments, the vaccine received its prequalification by the World Health Organization, a significant endorsement of its potential impact.

Development and approval of nOPV2

The ambitious effort to develop the nOPV2 vaccine required years of research, clinical trials, and strategic partnerships. By utilizing advanced genetic techniques, scientists were able to develop a vaccine with improved genetic stability. These modifications significantly reduce the risk of the virus reverting to a harmful form, thus minimizing the potential for cVDPV outbreaks.

The rigorous testing process included extensive clinical trials which showed promising results in both safety and effectiveness. The trials provided convincing data that nOPV2 is not only effective at inducing immunity but also better equipped to prevent the spread of vaccine-derived strains. In November 2020, the World Health Organization granted the vaccine an emergency use listing, a critical endorsement that allows its rapid distribution and deployment in outbreak regions.

This approval was a pivotal moment in polio eradication, marking the culmination of a concerted global effort. With nOPV2 now available, global health organizations can swiftly address cVDPV outbreaks, bringing us closer to the long-sought goal of eradicating polio in its entirety.

Key Characteristics of nOPV2

The nOPV2 vaccine incorporates several key characteristics that make it a significant improvement over previous oral polio vaccines:

  1. Genetic Stability:
    The most crucial enhancement is nOPV2’s genetic stability. It has been engineered to significantly reduce the chances of the weakened virus mutating back to a virulent form, a problem that has plagued earlier oral vaccines and led to outbreaks. This improved stability makes it far safer, especially in regions with low vaccination coverage.
  2. Safety and Efficacy:
    Extensive clinical trials and real-world testing have shown nOPV2 to be both safe and effective. It induces a strong immune response, ensuring robust protection against polio while minimizing the risk of side effects. This effectiveness is crucial in swiftly containing outbreaks and preventing further spread.
  3. Optimized Storage and Distribution:
    nOPV2 can be stored and transported at standard refrigeration temperatures of 2-8°C (35.6-46.4°F) for up to 6 months, and at a temperature of -20°C up to 24 months. This compatibility with existing cold chain infrastructure (such as vaccine refrigerators and freezers) simplifies its distribution and ensures its stability and potency. Such standard storage requirements make it ideal for deployment in regions with limited resources, where consistent refrigeration can be a challenge.
  4. Rapid Deployment:
    The vaccine’s emergency use listing by the World Health Organization (WHO) permits rapid deployment to regions experiencing cVDPV outbreaks. This quick access is essential for preventing outbreaks from spreading and safeguarding vulnerable populations.

Conclusion

The approval of the novel oral polio vaccine type 2 (nOPV2) signifies a major stride in the global fight against polio. With enhanced genetic stability, proven safety, and optimized storage conditions, it addresses key challenges in eradicating circulating vaccine-derived poliovirus. Its emergency use listing by the World Health Organization enables swift distribution to outbreak regions, helping to contain the virus more effectively. As we edge closer to a polio-free world, nOPV2 could be a key factor in the fight against this disease.

Close Popup

We use cookies that are necessary to ensure the proper functioning and security of the website. Additional cookies are only used with your consent. Analytics cookies are used to monitor website traffic and optimize your user experience, evaluate which marketing channels are performing better and analyze aggregated data about usage of the website. Functional cookies make it possible to improve the functionality and personalization of our site. They may be activated by us or by third parties whose services are used on the pages of our website. Advertising cookies are placed by third-party companies processing your data to create audiences lists to deliver targeted ads on social media and the internet. Please see our cookie policy to learn more about how they are used on our website. Click on "Accept all", to accept the use of such cookies and go directly to the website or click on “Reject all", to reject the use of all the cookies. Please click on “More options” to change your cookie preferences. You can also change your settings at any time in our Privacy Center.

Close Popup
Privacy Settings saved!
Privacy Settings

These cookies are necessary to ensure the proper functioning of our website or for security reasons. These enable the main functions of the website to be used. The processing of the data collected through these cookies is based on our legitimate interest. You can always choose not to accept these cookies on your device and delete them using the configuration settings of your web browser. However, this risks your user experience being seriously degraded and some functions of the website may even no longer be accessible.

Necessary cookies
  • test_cookie
  • wordpress_gdpr_cookies_declined
  • wordpress_gdpr_allowed_services
  • wordpress_gdpr_cookies_allowed
  • woocommerce_items_in_cart
  • woocommerce_cart_hash
  • wp_woocommerce_session_
  • NID
  • CONSENT
  • _GRECAPTCHA
  • __cf_bm
  • mtm_consent_removed

Decline all
Confirm your settings
Accept all